Strs Sells Shares in Kymera Therapeutics,

Trending News ☀️

Kymera Therapeutics ($NASDAQ:KYMR) is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts. Kymera is focused on the discovery and development of first-in-class small molecule drugs to modulate the activity of disease-causing proteins. The Ohio-based investment firm Strs has sold some of its shares in Kymera Therapeutics, Inc., resulting in a decrease in its stake in the company. Kymera’s stock price has been volatile in recent months, and Strs’s decision to sell shares may be due to concerns about the company’s future prospects.

Price History

On Monday, Kymera Therapeutics stock opened at $25.1 and closed at $25.1, up by 0.4% from last closing price of 25.0. Strs sold shares in the company, but it is not clear how many or at what price. Kymera Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat serious and life-threatening diseases. Live Quote…

About the Company

VI Analysis

Companies like KYMERA THERAPEUTICS that have achieved moderate revenue or earnings growth are classified as ‘rhinos’ according to the VI Star Chart. These companies are usually strong in asset and growth, but weak in dividend and profitability. Investors interested in KYMERA THERAPEUTICS may be looking for a company with good long-term potential. KYMERA THERAPEUTICS has an intermediate health score of 6/10 with regard to its cashflows and debt, which means it should be able to safely ride out any crisis without the risk of bankruptcy. However, investors should keep an eye on the company’s fundamentals in case they start to deteriorate. More…

VI Peers

The company is engaged in the discovery and development of first-in-class medicines to treat patients with severe and life-threatening diseases. Kymera Therapeutics Inc’s lead product candidate is KYM-001, which is in Phase I clinical trials for the treatment of patients with relapsed or refractory B-cell malignancies. The company’s competitors include Abionyx Pharma, Shattuck Labs Inc, and Prestige BioPharma Ltd.

– Abionyx Pharma ($LTS:0RAG)

Abionyx Pharma is a pharmaceutical company with a market cap of 52.78M as of 2022. The company has a Return on Equity of -37.6%. Abionyx Pharma is a company that focuses on the development and commercialization of innovative therapies for the treatment of cancer and other rare diseases.

– Shattuck Labs Inc ($NASDAQ:STTK)

Shattuck Labs Inc is a clinical-stage biopharmaceutical company. The company’s focus is on developing immunotherapy treatments for cancer. The company’s most advanced product candidate is an antibody-drug conjugate (ADC) that targets the protein CD70, which is expressed on the surface of many types of cancer cells.

– Prestige BioPharma Ltd ($KOSE:950210)

Prestige BioPharma Ltd is a biopharmaceutical company that focuses on the development, manufacture, and commercialization of innovative drugs for the treatment of cancer and other life-threatening diseases. The company has a market cap of 98.44B as of 2022 and a ROE of -28.18%. Prestige BioPharma’s products are designed to target specific molecular pathways that are involved in the development and progression of cancer. The company’s lead product candidates are PBP-101, an orally-available small molecule inhibitor of the checkpoint kinase 1 (Chk1) enzyme, and PBP-102, an antibody-drug conjugate that targets the epidermal growth factor receptor 2 (HER2).

Summary

Investors may be interested in Kymera Therapeutics, Inc. because it is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat patients with cancer. The company’s most advanced product candidate is its lead program, which is currently in a Phase 1/2 clinical trial in patients with relapsed or refractory B-cell malignancies. Kymera is also developing additional programs in other oncology indications. The company’s technology platform is based on its proprietary TurboTAA platform, which is designed to specifically target tumor-associated antigens .

TAA are proteins that are overexpressed on the surface of cancer cells and are thought to play a role in cancer progression. Kymera’s TurboTAA platform is designed to specifically target and destroy cancer cells while sparing normal cells.